A Study of NZV930 Alone or in Combination with PDR001 and/or NIR178 in Patients with Advanced Solid Tumours

Trial ID: NCT03549000


The drugs in this trial – NZV930, PDR001 and NIR178 – are experimental immunotherapies that work by reactivating the body’s own immune response to target and destroy cancer cells.

PDR001 works in a similar fashion to other approved immunotherapies such as pembrolizumab (Keytruda®). Meanwhile, NZV930 and NIR178 work by targeting a new potential cancer-target called adenosine.

These drug names are just placeholders provided by the pharmaceutical company for the duration of the trial.

The Trial:

This study will investigate the safety and effectiveness of NZV930 used by itself, as well as in the combination of NZV930 with PDR001 and/or NIR178. Accordingly, you may be enrolled on any one of four treatment groups:

  • NZV930 alone
  • NZV930 with PDR001
  • NZV930 with NIR178
  • NZV930 with NIR178 & PDR001

This study is specifically designed for patients with advanced kidney cancer who have completed standard therapy and whose cancer has continued to grow despite treatment.

Basic Eligibility:

  • All subtypes eligible
  • Cancer has spread or cannot be removed by surgery
  • Must have completed all standard therapies (no further drugs are available)
  • Must be able and willing to undergo a tumour biopsy

Additional eligibility criteria will apply. Please speak to your doctor.


Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentrePrincess Margaret Cancer Centre Principal InvestigatorNot given LocationToronto, ON Trial StatusRecruiting
Hospital / Cancer CentreNovartis Investigative Site - Quebec Principal Investigator LocationMontreal, QB Trial StatusRecruiting
Do NOT follow this link or you will be banned from the site!